| Dr William Sidney Young, PHD | |
|
747 S Paradise Canyon Rd, Suite 2, Cedar City, UT 84720-3175 | |
| (435) 865-9119 | |
| (435) 865-9115 |
| Full Name | Dr William Sidney Young |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 31 Years |
| Location | 747 S Paradise Canyon Rd, Cedar City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669602884 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 346225-2501 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Psychological Counseling And Consulting Pc | 8022350677 | 2 |
News Archive
In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.
A new short-term pilot study in children and teens 6-17 years old with attention-deficit hyperactivity disorder has shown saffron to be as effective at controlling symptoms as methylphenidate, the commonly prescribed drug Ritalin.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 2 days ago
| Entity Name | Premier Psychological Counseling And Consulting Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235460312 PECOS PAC ID: 8022350677 Enrollment ID: O20190430002487 |
News Archive
In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.
A new short-term pilot study in children and teens 6-17 years old with attention-deficit hyperactivity disorder has shown saffron to be as effective at controlling symptoms as methylphenidate, the commonly prescribed drug Ritalin.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Sidney Young, PHD 747 S Paradise Canyon Rd, Suite 2, Cedar City, UT 84720-3175 Ph: (435) 865-9119 | Dr William Sidney Young, PHD 747 S Paradise Canyon Rd, Suite 2, Cedar City, UT 84720-3175 Ph: (435) 865-9119 |
News Archive
In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.
A new short-term pilot study in children and teens 6-17 years old with attention-deficit hyperactivity disorder has shown saffron to be as effective at controlling symptoms as methylphenidate, the commonly prescribed drug Ritalin.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to grow through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 2 days ago
Curtis L Hill, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1921 W 546 S, Cedar City, UT 84720 Phone: 435-865-8225 | |
Dr. Melissa Leilani Devencenzi, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 732 S 2075 W, Cedar City, UT 84720 Phone: 951-264-0798 | |
Dr. Kirsten Leigh Graham, PH.D. Psychologist Medicare: Medicare Enrolled Practice Location: 351 W University Blvdgeneral Classrooms 308-o, General Classrooms 308-o, Cedar City, UT 84720 Phone: 435-277-0285 | |
Brett Shumway, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 646 S Main St # 207, Cedar City, UT 84720 Phone: 435-327-0176 | |
Steve T Barney, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 245 E 680 S, Cedar City, UT 84720 Phone: 435-867-7654 Fax: 435-986-8700 |